Promising COVID-19 therapeutic drug to start phase 3 clinical trial in the United States
Recruitment of first U.S.-based patients in dapsone trial has started
The Canadian Longitudinal Study on Aging targets brain health
Thanks to the Weston Family Foundation, the CLSA will employ MRI imaging and microbiome analyses to investigate cognitive aging
RI-MUHC study shows impact of combinatorial immunotherapy on an aggressive cancer
A combinatorial immunotherapy may provide significant therapeutic benefit in managing pancreatic ductal...
RI-MUHC team studies a novel, fully automated insulin delivery system
A new publication in Lancet Digital Health describes an important step that may improve glucose control and quality of life for people with type 1...
Can inhaled corticosteroids alleviate early symptoms of COVID-19?
Results from the CONTAIN study conducted at the RI-MUHC reveal that ciclesonide is no better than placebo
Regular screening for tuberculosis in Inuit communities is cost-effective
A new study from RI-MUHC researchers published in CMAJ recommends regular screening to help reduce outbreaks
RI-MUHC team detects impact of HIV antiretroviral therapy on the anti-tuberculosis immune response
Alveolar macrophages, cells important for protection from tuberculosis infection, are adversely impacted by...
The 2021 RI-MUHC Annual Report is online!
An invitation from Dr. Rhian Touyz
Discovery of mechanics of drug targets for COVID-19
Scientists unravel inner workings of cell receptors involved in inflammatory diseases
RI-MUHC researchers tackle COVID-19 vaccine hesitancy in adults and in children
Videos from projects led by Drs. Inés Colmegna and Moshe Ben-Shoshan are now available